<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02679248</url>
  </required_header>
  <id_info>
    <org_study_id>15NBHN</org_study_id>
    <nct_id>NCT02679248</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Effect of a Nitric Oxide Supplementation on Pre- and Mildly Hypertensive Adults</brief_title>
  <acronym>15NBHN</acronym>
  <official_title>A Double Blind, Placebo Controlled Parallel Study to Investigate the Effect of a Nitric Oxide Supplementation Product on Pre- and Mildly Hypertensive Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KGK Science Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Neogenis Laboratories</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>KGK Science Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the effect of a nitric oxide supplementation product, Neo40&#xD;
      Daily®, on blood pressure in pre-hypertensive and mildly hypertensive adults. Subjects will&#xD;
      take 2 lozenges per day 12 hours apart for 8 weeks. Half of the subjects will receive Neo40&#xD;
      Daily® and the other half of the subjects will receive placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">February 3, 2016</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">February 3, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Daytime Systolic BP</measure>
    <time_frame>8 weeks</time_frame>
    <description>Mean ambulatory BP measured from 8am to 8pm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daytime Diastolic BP</measure>
    <time_frame>8 weeks</time_frame>
    <description>Mean ambulatory BP measured from 8am to 8pm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour BP</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measured with ambulatory BP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Night-time BP</measure>
    <time_frame>8 weeks</time_frame>
    <description>Mean ambulatory BP measured from 12am to 6am</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BP Variability</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measured with ambulatory BP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seated BP</measure>
    <time_frame>8 weeks</time_frame>
    <description>Seated, resting BP measured in office</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Assay: Lipid Profile</measure>
    <time_frame>8 weeks</time_frame>
    <description>Total cholesterol, HDL-cholesterol, LDL-cholesterol, total triglycerides, ApoB, ApoA1, sdLDL, Lp(a)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum or Plasma Assay: Inflammatory Markers</measure>
    <time_frame>8 weeks</time_frame>
    <description>MPO, LP-PLA2, hsCRP, ADMA/SDMA, oxLDL</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of subjects with abnormal haematology</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of subjects with abnormal clinical chemistry</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of subjects with abnormal kidney function</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of subjects with abnormal liver function</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of subjects with abnormal blood electrolytes</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of subjects with abnormal blood pressure</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of subjects with abnormal heart rate</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>8 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Pre-hypertension</condition>
  <arm_group>
    <arm_group_label>Neo40 Daily®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Neo40 Daily®</intervention_name>
    <arm_group_label>Neo40 Daily®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  If female, subject is not of child bearing potential, which is defined as females who&#xD;
             have had a hysterectomy or oophorectomy, bilateral tubal ligation or are&#xD;
             post-menopausal (natural or surgically with &gt; 1 year since last menstruation) OR&#xD;
             Females of childbearing potential must agree to use a medically approved method of&#xD;
             birth control and have a negative urine pregnancy test result. Acceptable methods of&#xD;
             birth control include:&#xD;
&#xD;
               -  Hormonal contraceptives including oral contraceptives, hormone birth control&#xD;
                  patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable&#xD;
                  contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)&#xD;
&#xD;
               -  Double-barrier method&#xD;
&#xD;
               -  Non-hormonal intrauterine devices&#xD;
&#xD;
               -  Vasectomy of partner&#xD;
&#xD;
          -  BMI 18.5-29.9 kg/m2 (±1 kg/m2)&#xD;
&#xD;
          -  Seated resting systolic blood pressures between 130-150 mmHg (inclusive) and diastolic&#xD;
             blood pressure ≤ 100 mmHg at screening visit&#xD;
&#xD;
          -  Agreement to maintain current level of physical activity and diet throughout the study&#xD;
&#xD;
          -  Agrees to comply with study procedures including willingness to fast at least 12 hours&#xD;
             before blood samples, abstain from alcohol two days prior to blood sampling and blood&#xD;
             pressure measurement, abstain from coffee at least 14 hours before blood pressure&#xD;
             measurement and abstain from physical exercise at least 4 hours before and during&#xD;
             blood pressure measurement&#xD;
&#xD;
          -  Has given voluntary, written, informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has given voluntary, written, informed consent to participate in the study&#xD;
&#xD;
          -  Use of medication for the treatment of hypertension&#xD;
&#xD;
          -  Use of prescription diuretics&#xD;
&#xD;
          -  Use of natural health products for the treatment of hypertension within 2 weeks of&#xD;
             screening (e.g. garlic supplements, french lavender supplements, cardamom supplements,&#xD;
             cinnamon supplements, basil supplements, hawthorn cats claw and celery seed&#xD;
             supplements)&#xD;
&#xD;
          -  Significant cardiac history defined as a history of myocardial infarction (MI);&#xD;
             coronary angioplasty or bypass graft(s); Valvular disease or repair; unstable angina&#xD;
             pectoris; transient ischemic attack (TIA); cerebrovascular accidents (CVA); congestive&#xD;
             heart failure; coronary artery disease (CAD); or angina (stable or unstable)&#xD;
&#xD;
          -  Type I or Type II diabetes&#xD;
&#xD;
          -  Diagnosis of hypertensive retinopathy, left ventricular dysfunction or peripheral&#xD;
             artery disease&#xD;
&#xD;
          -  Abnormal electrolytes, liver or kidney function&#xD;
&#xD;
          -  Diagnosis of secondary hypertension&#xD;
&#xD;
          -  Diagnosis of anemia&#xD;
&#xD;
          -  Unstable medical conditions that in the opinion of the Qualified Investigator preclude&#xD;
             the volunteer from participating in the study&#xD;
&#xD;
          -  Alcohol or drug abuse within the last 6 months&#xD;
&#xD;
          -  Use of medicinal marijuana&#xD;
&#xD;
          -  Clinically significant abnormal laboratory results at screening&#xD;
&#xD;
          -  Participation in a clinical research trial within 30 days prior to randomization&#xD;
&#xD;
          -  Allergy or sensitivity to study supplement ingredients&#xD;
&#xD;
          -  Individuals who are cognitively impaired and/or who are unable to give informed&#xD;
             consent&#xD;
&#xD;
          -  Any other condition which in the Investigator's opinion may adversely affect the&#xD;
             subject's ability to complete the study or its measures or which may pose significant&#xD;
             risk to the subject&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tetyana Pelipyagina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KGK Science Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KGK Synergize Inc.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manna Research - Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>February 3, 2016</study_first_submitted>
  <study_first_submitted_qc>February 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2016</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pre-hypertension</keyword>
  <keyword>Mild hypertension</keyword>
  <keyword>Dietary supplement</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Nitric oxide</keyword>
  <keyword>Neo40 Daily</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Prehypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

